← Leaderboards
Suzanne Louise Topalian
University Of Md Biotechnology Institute
$3,615,172
Attributed
$9,867,787
Total exposure
2
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $899K · FY2008–25$1M$750K$500K$250K$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$9,867,787 · 2
By mechanism
R01$9,867,787 · 2
Top collaborators
- Drew M. Pardoll15 shared
- Janis M. Taube10 shared
- Lieping Chen5 shared
- Roy A Mariuzza5 shared
Most similar at University Of Md Biotechnology Institute
Same institution · by research overlap
- John Orban$6,103,953
- Osnat Herzberg$10,660,821
Others in their field
Top investigators on “Immunotherapy”
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,653,178
- Constance Ann Benson · University Of California, San Diego$150,079,712
- Joseph Sparano · Montefiore Medical Center (Bronx, Ny)$111,361,061
- Robert H Vonderheide · University Of Pennsylvania$84,159,371
- Sharon A Nachman · Johns Hopkins University$74,725,055
- Todd A Alonzo · University Of Colorado Denver/Hsc Denver$72,436,447
Research focus
ImmunotherapyCellsMelanomaT-LymphocyteSignal TransductionMalignant NeoplasmsLigandsTumorCytokineBaseResponseMolecularComplexClinical ApplicationNeoplastic CellCell TypeReceptorCancer ImmunotherapyBlocking AntibodiesInterferon Type IiIn VitroImmune SystemCancer TherapyImmunity
Grant awards (20)
PD-1/PD-L1 modulation in cancer therapy$600,140
R01 · FY2025 · CA
PD-1/PD-L1 modulation in cancer therapy$570,133
R01 · FY2024 · CA
PD-1/PD-L1 modulation in cancer therapy$600,140
R01 · FY2023 · CA
PD-1/PD-L1 modulation in cancer therapy$588,135
R01 · FY2022 · CA
PD-1/PD-L1 modulation in cancer therapy$600,139
R01 · FY2021 · CA
PD-1/PD-L1 modulation in cancer therapy$672,206
R01 · FY2020 · CA
PD-1/PD-L1 modulation in cancer therapy$473,681
R01 · FY2019 · CA
PD-1/PD-L1 modulation in cancer therapy$488,332
R01 · FY2018 · CA
PD-1/PD-L1 modulation in cancer therapy$488,332
R01 · FY2017 · CA
PD-1/PD-L1 modulation in cancer therapy$488,332
R01 · FY2016 · CA
B7-H1/PD-1 modulation in cancer therapy$443,937
R01 · FY2014 · CA
B7-H1/PD-1 modulation in cancer therapy$437,199
R01 · FY2013 · CA
B7-H1/PD-1 modulation in cancer therapy$471,842
R01 · FY2012 · CA
Recognition of Self and Mutated Self by Autoimmune and Tumor-Specific TCRs$384,690
R01 · FY2012 · AI
B7-H1/PD-1 modulation in cancer therapy$479,334
R01 · FY2011 · CA
Recognition of Self and Mutated Self by Autoimmune and Tumor-Specific TCRs$384,690
R01 · FY2011 · AI
B7-H1/PD-1 modulation in cancer therapy$510,450
R01 · FY2010 · CA
Recognition of Self and Mutated Self by Autoimmune and Tumor-Specific TCRs$388,575
R01 · FY2010 · AI
Recognition of Self and Mutated Self by Autoimmune and Tumor-Specific TCRs$392,500
R01 · FY2009 · AI
Recognition of Self and Mutated Self by Autoimmune and Tumor-Specific TCRs$405,000
R01 · FY2008 · AI